Lunke Medical Completes Series A Funding Round Led by Bangqin Capital to Advance Integrated High-Pressure Contrast Injection Solutions

Recently, Shenzhen Lenko Medical Technology Co., Ltd. (hereinafter referred to as “Lenko”) announced the completion ofTens of millions of yuan in Series ARound of Financing. This round of financing was led byBIOCHING CAPITALLead Investor, Senior Industry InvestorGuocheng Dejun Investmentwith co-investment. This round also marks the company’s second financing since its establishment in May 2024, underscoring strong recognition from the capital markets of Lenko Medical’s management team, product competitiveness, and industry potential.

Following the completion of this funding round, Lenko will further increase its investment in core technologies and product platforms for high-pressure contrast media injection, enrich its product matrix for comprehensive high-pressure contrast solutions, accelerate the domestic substitution of high-end high-pressure injectors, and simultaneously advance overseas market expansion to build an internationally competitive integrated platform for high-pressure contrast injection devices and consumables.

High-pressure contrast injection systems are critical equipment for interventional procedures and enhanced scanning in radiology departments. They are widely used in clinical scenarios such as CT enhancement, MRI enhancement, and cardiovascular interventions, characterized by high technical barriers, stringent safety requirements, and strong customer stickiness. For a long time, the high-end market in this field has been dominated by European and American manufacturers, resulting in high product and service costs, as well as insufficient localization and clinical adaptability. This presents significant opportunities for domestic substitution.

Lenko entered the high-barrier niche of high-pressure contrast injection. Centered on clinical needs, it has continuously accumulated core technologies in system control, precision fluid delivery, materials, and sensing. It was the first to establish a presence in the two mainstream technical pathways—high-end peristaltic pump-based and syringe-type high-pressure injectors—and has built an integrated business model combining electromechanical devices, polymer consumables, and biosensors, laying the foundation for long-term scalable growth.

At the core product level, Lenko has established a product matrix centered on the Nova UC3000 series peristaltic pump-based three-channel high-pressure injectors and the Magic A1000/C2000/M2000 series syringe-type high-pressure injectors, complemented by a comprehensive range of consumable solutions covering multiple clinical scenarios.

Among these features, the “Precise Dual-Stream Mixed Injection” (non-segmented injection) function equipped in the Nova UC3000 series has been filed for an invention patent. This patent is wholly owned by Lenko as independent intellectual property and represents the only patent of its kind globally in the field of peristaltic pump-based three-channel high-pressure injectors, making the Nova UC3000 series the only product worldwide that truly achieves precise dual-stream mixed injection. This capability holds significant clinical value in complex contrast-enhanced scanning and coronary contrast-enhancement scenarios, and constitutes the company’s core technological barrier in the global market.

Since its establishment, Lenko has achieved rapid and coordinated progress in product R&D, registration, marketing, and channel development. In the domestic market, the company’s business has covered more than30 Provinces and Municipalities, high-pressure injector equipment has been in"Numerous Leading Tier-3 Teaching Hospitals Across China"Its use has established a strong clinical reputation and demonstrated a positive model effect.

In the international market, the company's products have enteredMore than 20 countries and regions, and by participating in major global medical exhibitions and academic conferences such as China CMEF, Germany MEDICA, and ARAB HEALTH, to accelerate the establishment of brand awareness and channel networks, laying the foundation for subsequent large-scale international expansion.

Lenko’s core team hails from Mindray Medical and the Changchun Institute of Optics, Fine Mechanics and Physics of the Chinese Academy of Sciences. Guided by the values of “Passion and Integrity” and adhering to a philosophy of rational long-termism, Lenko has assembled a group of senior industry experts from leading medical device companies in China and abroad. The company possesses a complete capability loop, spanning from foundational technology development and product engineering to global market expansion.

With the completion of this round of financing, Lenko will continue to increase its investment in core technology platforms, product pipelines, and team building, strengthen its system-level competitive advantages in the field of high-pressure contrast imaging, promote the transition from “domestic substitution” to “global competition,” and strive to grow into a global benchmark innovative medical device enterprise integrating electromechanical equipment, polymer consumables, and biosensing.